Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Genes that may be involved
  • Substrate of
  • Drug Interactions
  • Dosage
  • Nutrition/Nutraceutical Interactions
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Opatanol; Belgium: Opatanol; Bulgaria: Opatanol; Cyprus: Opatanol; Czech Republic: Opatanol; Denmark: Opatanol; Estonia: Opatanol; Finland: Opatanol; France: Opatanol; Germany: Opatanol; Greece: Opatanol; Hungary: Opatanol; Ireland: Opatanol; Italy: Opatanol; Latvia: Opatanol; Lithuania: Opatanol; Luxembourg: Opatanol; Malta: Opatanol; Netherlands: Opatanol; Poland: Opatanol; Portugal: Opatanol; Romania: Opatanol; Slovakia: Opatanol; Slovenia: Opatanol; Spain: Opatanol; Sweden: Opatanol; UK: Opatanol.

North America

Canada: Patanol; USA: Pataday, Patanase, Patanol.

Latin America

Argentina: Olopat, Patanol, Patanol-S, Zoloatlas; Brazil: Patanol; Mexico: Patanol.


Japan: Allelock.

Drug combinations


Olopatadine Hydrochloride: C~21~H~23~NO~3~ HCl. Mw: 373.88. 11-[(Z)-3(Dimethylamino) propylidene]-6-11-dihydrodibenz[b,e] oxepin-2-acetic acid, hydrochloride. CAS-140462-76-6.

Pharmacologic Category

EENT Preparations; Antiallergic Agents. Histamine H~1~ Antagonist, Nasal and Ophthalmic Solution. (ATC-Code: R01AC08; S01GX09).

Mechanism of action

Olopatadine is a mast cell stabilizer and a histamine H~1~ antagonist. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.

Therapeutic use

Olopatadine solution is a mast cell stabilizer indicated for the treatment of ocular itching associated with allergic conjunctivitis.

Pregnancy and lactiation implications

Animal studies showed a decrease in neonatal survival and body weight. Because animal studies are not always predictive of human responses, should be used in pregnant women only if potential benefit to mother justifies potential risk to embryo or fetus. Caution should be exercised in nursing mothers.

Unlabeled use


None known to date.

Warnings and precautions

Ophthalmic solution: For topical ocular use only. As with any eye drop, to prevent contaminating the dropper tip and solution, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle. Keep bottle tightly closed when not in use. Patients should be advised not to wear a contact lens if the eye is red. Should not be used to treat contact lens-related irritation. The preservative in olopatadine solution, benzalkonium chloride, may be absorbed by soft contact lenses (wait at least ten minutes after instilling solution before inserting contact lenses). Symptoms similar to cold syndrome and pharyngitis have been reported.

Nasal spray: May cause drowsiness in some patients; instruct patient to use caution when driving or operating machinery. Effects may be additive with CNS depressants and/or ethanol. Periodically examine nasal mucosa for ulceration and consider discontinuing if ulceration occurs.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart